An unusually presenting case of sCJD-The VV1 subtype

Clinical Neurology and Neurosurgery

Volumn 111, Issue 3, 2009, Pages 282-291

  Tanev, Kaloyan S ^a   Yilma, Mimi ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Biomarkers; Creutzfeldt Jakob disease; Dementia; Electroencephalography; Magnetic resonance imaging; Neuroimaging; Prion diseases

Indexed keywords

ACICLOVIR; AMFEBUTAMONE; ANTIBIOTIC AGENT; BACLOFEN; ETIRACETAM; LORAZEPAM; METHYLPHENIDATE; PRION PROTEIN; RISPERIDONE; SERTRALINE; TRAZODONE;

ADL DISABILITY; ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CASE REPORT; CELLULITIS; COGNITIVE DEFECT; CONVERSION DISORDER; CREUTZFELDT JAKOB DISEASE; DEPRESSION; EEG ABNORMALITY; ELECTROENCEPHALOGRAM; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANOIA; PATHOPHYSIOLOGY; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SLOW WORD ARTICULATION; SPEECH DISORDER; SPORADIC CREUTZFELDT JAKOB DISEASE SUBTYPE VV1; WORD ERROR;

ADULT; BRAIN; CREUTZFELDT-JAKOB SYNDROME; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; FATAL OUTCOME; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MUSCLE SPASTICITY; PRIONS;

EID: 60349131457     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2008.09.017     Document Type: Article

References (32)

1. Prusiner S.B. Novel proteinaceous infectious particles cause scrapie. Science 216 April (4542) (1982) 136-144
2. Prusiner S. Prions. Proc Natl Acad Sci 95 (1998) 13363-13383
3. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry 76 (2005) 906-919
4. Parchi P., Giese A., Capellari S., Brown P., Schulz-Schaeffer W., Windl O., et al. Classification of sporadic Creutzfeldt-Jacob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46 (1999) 224-233
5. Gambetti P., Kong Q., Zou W., Parchi P., and Chen S. Sporadic and familial CJD: classification and characterization. Br Med Bull 66 (2003) 213-239
6. Heinemann U., Krasnianski A., Meissner B., Varges D., Kallenberg K., Shulz-Schaeffer W.J., et al. Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. Brain 130 (2007) 1350-1359
7. Heinemann U., Krasnianski A., Meissner B., Gloeckner S.F., Kretzschmar H.A., and Zerr I. Molecular subtype-specific clinical diagnosis of prion diseases. Vet Microbiol 123 August (14) (2007) 328-335 [Epub 2007 April 7]
8. Meissner B., Westner I.M., Kallenberg K., Krasnianski A., Bartl M., Varges D., et al. Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology 65 (2005) 1544-1550
9. World Health Organization: report of a WHO consultation on global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies. Geneva, Switzerland: WHO. February 9-11, 1998. WHO/EMC/ZDI/98.9.
10. World Health Organization, Weekly epidemiological record 1998, 73, 361-372.
11. Yen C.F., Lin R.T., Liu C.K., Lee P.W., Chen C.C., and Chang Y.P. The psychiatric manifestation of Creutzfeldt-Jakob disease. Kaohsiung J Med Sci 13 April (4) (1997) 263-267
12. Tschampa H.J., Neumann M., Zerr I., Henkel K., Schroter A., Shulz-Scaheffer W.J., et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Nerusurg Psychiatry 71 (2001) 33-39
13. Steinhoff B.J., Räcker S., Herrendorf G., Poser S., Grosche S., Zerr I., et al. Accuracy and reiability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. Arch Neurol 53 162 (1996)
14. Zerr I., Pocchiari M., Collins S., Brandel J.P., de Pedro Cuesta J., Knight R.S., et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 26 (2000) 811-815
15. Castellani R.J., Colucci M., Xie Z., Zou W., Li C., Parchi P., et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jacob disease. Neurology 63 (2004) 436-442
16. Kenney K., Hsich G., Brechtel C., and Gibbs C.J. The cerebrospinal fluid 14-3-3 assay's diagnostic utility among clinically suspected Creutzfeldt-Jakob disease patients: the NIH experience. Neurol 58 Suppl 3 (2002) A250
17. Cuadrado-Corrales N., Jiménez-Huete A., Albo C., Hortigüela R., Vega L., Cerrato L., et al. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. BMC Neurol 6 (2006) 25
18. Geschwind M.D., Martindale J., Miller D., DeArmond S.J., Uyehara-Lock J., Gaskin D., et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 60 (2003) 813
19. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43 (1998) 32
20. Chapman T., McKeel Jr. D.W., and Morris J.C. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 55 (2000) 1396
21. Satoh J., Jurohara K., Yukitake M., and Kuroda Y. The 14-3-3 protein detectable in the cerevrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol 41 (1999) 216
22. Collie D.A., Sellar R.J., Zeidler M., Colchester A.C., Knight R., and Will R.G. MRI of Creutzfeldt-Jacob disease: imaging features and recommended MRI protocol. Clin Radiol 56 (2001) 726-739
23. Schröter A., Zerr I., Henkel K., Tschampa H.J., Finkenstaedt M., and Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 57 (2000) 1751-1757
24. Henkel K., Zerr I., Hertel A., Gratz K.F., Schröter A., Tschampa H.J., et al. Positron emission tomography with [(18)F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD). J Neurol 249 June (6) (2002) 699-705
25. Nakajima M., Yamada T., Kusuhara T., Furukawa H., takahashi M., Yamauchi A., et al. results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disorders 17 3 (2004) 158-163
26. Kobayashi Y., Hirata K., Tanaka H., and Yamada T. Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft-an EEG evaluation. Clin Neurol 43 July (7) (2003) 403-408
27. Muller W.E., Laplanche J.L., Ushijima H., and Schroder H.C. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech Ageing Dev 116 July (2-3) (2000) 193-218
28. Dyer O. Research groups fail to reach agreement on protocol for treatment trials for CJD. BMJ March (328) (2004) 603
29. Dyer O. Family finds hospital willing to give experimental CJD treatment. BMJ 8 (2003 Jan) 326
30. Otto M., Cepek L., Ratzka P., Doehlinger S., Boekhoff I., Wiltfang J., et al. Efficacy of flupirtine on cognitive function in patients with CJD. Neurology 62 (2004) 714-718
31. Collins S.J., Sanchez-Juan P., Masters C.L., Klug G.M., van Duijn C., Poleggi A., et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 129 September (Pt 9) (2006) 2278-2287 [Epub 2006 July 1]
32. Worrall B.B., Herman S.T., Capellari S., Lynch T., Chin S., Gambetti P., et al. Type 1 protease resistant prion protein and valine homozygosity at codon 129 of PRNP identify a subtype of sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 67 November (5) (1999) 671-674